Shubham Jaiswal (firstname.lastname@example.org)
The Serum Institute of India said on Tuesday it plans this year to produce up to 60 million doses of a potential vaccine against the new coronavirus that is under clinical trial in Britain.
Serum is the world largest vaccines’ maker by volume, is mass-producing the vaccine candidate developed by the University of Oxford, which started testing it on humans last week, and is a leader within the global race to develop an antidote to the novel coronavirus.
Some 3.05 million people infected globally and 211,376 have died from COVID-19, the respiratory illness caused by the coronavirus, consistent with a Reuters tally.
While the Oxford vaccine, called, “ChAdOx1 nCoV-19”, is yet to be proven to figure against COVID-19, Serum decided to start out manufacturing it because it had shown success in animal trials and had progressed to the tests on human body, Serum Chief Executive Adar Poonawalla said.